COVID-19 has raised the issue of using traditional medicines to battle contemporary diseases, and the endorsement clearly encouraged testing with criteria similar to those used for molecules developed by labs in Asia, Europe or the Americas, AFP reported.

It came months after a bid by the president of Madagascar to promote a drink based on Artemisia, a plant with proven efficacy in malaria treatment, was met with widespread scorn.

On Saturday, WHO experts and colleagues from two other organizations “endorsed a protocol for phase III clinical trials of herbal medicine for COVID-19 as well as a charter and terms of reference for the establishment of a data and safety monitoring board for herbal medicine clinical trials,” a statement said.

“Phase III clinical trials are pivotal in fully assessing the safety and efficacy of a new medical product,” it noted.

“If a traditional medicine product is found to be safe, efficacious and quality-assured, WHO will recommend (it) for a fast-tracked, large-scale local manufacturing,” Prosper Tumusiime, a regional WHO director, was quoted as saying.

WHO’s partners are the Africa Centre for Disease Control and Prevention and the African Union Commission for Social Affairs.

“The onset of COVID-19, like the Ebola outbreak in West Africa, has highlighted the need for strengthened health systems and accelerated research and development programs, including on traditional medicines,” Tumusiime said.

He did not refer specifically to the Madagascar drink COVID-Organics, also called CVO, that President Andry Rajoelina has pitched as a cure for the virus, however.

It has been widely distributed in Madagascar and sold to several other countries, mainly in Africa.

In May, WHO Africa Director Matshidiso Moeti told media that African governments had committed in 2000 to taking “traditional therapies” through the same clinical trials as other medication.

“I can understand the need, the drive to find something that can help,” Moeti said. “But we would very much like to encourage this scientific process in which the governments themselves made a commitment.”

National Health Service Blood and Transplant (NHSBT) is asking people who have recovered from COVID-19 to donate their blood so they can assess the therapy in trials, BBC reported.

The hope is that the antibodies they have built up will help to clear the virus in others.

The US has already started a major project to study this, involving more than 1,500 hospitals.

When a person has COVID-19, their immune system responds by creating antibodies, which attack the virus.

Over time these build up and can be found in the plasma, the liquid portion of the blood.

NHSBT now wants to collect the plasma from recovered COVID-19 patients to see if it can be given to people who are currently ill with the virus.

A statement from the organization said: “We envisage that this will be initially used in trials as a possible treatment for COVID-19.

“If fully approved, the trials will investigate whether convalescent plasma transfusions could improve a COVID-19 patient’s speed of recovery and chances of survival.

“All clinical trials have to follow a rigorous approval process to protect patients and to ensure robust results are generated. We are working closely with the government and all relevant bodies to move through the approvals process as quickly as possible.”

Several groups in the UK have been looking into using blood plasma.

University Hospital of Wales (UHW) in Cardiff announced this week that it wanted to trial the technology.

Professor Sir Robert Lechler, president of the Academy of Medical Sciences and executive director of King’s Health Partners, which includes King’s College London and three major London hospitals, is also hoping to set up another small-scale trial.

He wants to use plasma for seriously ill patients that have no other treatment options, while a larger national trial is getting underway.

He said: “I would be disappointed if we weren’t able to see some patients given this form of therapy within a couple of weeks. Let’s hope that the NHSBT national trial gets into gear really quickly.”

He said the UK had moved slowly to test the treatment.

“I think there are many aspects of this pandemic we’ll look back on and say, I wonder why we didn’t move a little bit faster. I think this could be one of those”.

Around the world, trials are now underway to look at using plasma.

In just three weeks, scientists in the US have organized a nationwide project and about 600 patients have been treated so far.

Professor Michael Joyner, from the Mayo Clinic, is leading the work.

He said: “The thing we’ve learned in the first week of administration is that no major safety signals have emerged and administration of the product does not appear to be causing a whole lot of unanticipated side effects.

“There are anecdotal reports of oxygenation improving and other patient improvements. Those are certainly heartening, but they need to be rigorously evaluated.”

He said the therapy was “rough and ready”.

“There’s a lot we don’t understand about the plasma. We’re going to learn more about what’s in the plasma, the components, the antibody levels, and other factors that may be there as the weeks go on.

“But sometimes, as a physician, you just have to try to take a shot on goal when you have a shot.”

Harnessing the blood of recovered patients is not a new idea in medicine. It was used more than 100 years ago during the Spanish Flu epidemic, and more recently for Ebola and SARS.

So far, only small studies have looked at its efficacy, and there is a great deal of research that needs to be done to see how effective it will be against coronavirus.

But in the US, they say they have no shortage of people who want to help.

Bruce Sachais, chief medical officer at the New York Blood Center, said: “People have been amazing. They keep coming out in droves.

“We have hundreds and hundreds of donors and we’ve been able to collect over 1,000 units already. It’s really heart-warming to see that for people who have gone through the infection, in various degrees, their main concern is ‘how can I now help others?'”

Scientists say plasma won’t be a magic bullet.

But while our options for treating coronavirus are so limited, the hope is it could help until a vaccine is found.